🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Nathan D. Seligson

University of North Florida

ORCID: 0000-0002-9670-3792

Also affiliated with Jacksonville University, Nemours Children's Health System, Florida College

MedicineBiochemistry, Genetics and Molecular BiologyPharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.618Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009472
Top 32%
0.618DataRank
Top 32%16 citations

James L. Chen, Austin C Goodrich, Brian A. Van Tine, Jordan D. Campbell, Allison L. Richards +9 more

Papers

Driven by 4 papers — median percentile 68. Top paper: “A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses”.

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009472
Top 32%
0.618DataRank
Top 32%16 citations

James L. Chen, Austin C Goodrich, Brian A. Van Tine, Jordan D. Campbell, Allison L. Richards +9 more

Association ofANRILPolymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation

Anticancer Research(2020)10.21873/anticanres.14585
N/A
0DataRank · unranked
7 citations

Nathan D. Seligson, Xuejie Zhang, Jasmine A. Johnson, Zachary VanGundy, Daqing Wang +5 more

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML

Blood Advances(2022)10.1182/bloodadvances.2022007934
N/A
0DataRank · unranked
15 citations

Roya Rafiee, Abderrahmane Tagmount, Amin Sobh, Alex Loguinov, Angelica K. de Jesus Sosa +12 more

CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation

Frontiers in Pharmacology(2024)10.3389/fphar.2023.1334440
N/A
0DataRank · unranked
8 citations

Xunjie Zhang, Mark Zemanek, Jasmine A. Johnson, Zachary VanGundy, Daqing Wang +6 more